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Leishmaniasis
Vaccine Development
1
Animals as Models and Patients
VACCINE TECHNOLOGY IV, Albufeira, 2012
Summary: The Ideal Leishmania 
Vaccine
• Safe
• Induces effective T cell response against appropriate 
antigens
• Induces long-term immunity
• Prophylactic and therapeutic activity
• Effective against more than one form of 
leishmaniasis
• Cost-effective
• Reproducible, transferable manufacturing process
Next Generation Vaccines Against 
Leishmaniasis          
Macrophage infected with 
amastigotes
Leishmaniasis:  Multiple Forms, 
Multiple Diseases 
• Humans 
—VL (Visceral Leishmaniasis)
—CL (Cutaneous Leishmaniasis)
—ML (Mucosal Leishmaniasis)
• Canines
—VL
—CL
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Human VL:  The Problem
• A global disease:  200 million people at risk in 70 countries
— Over 90% of cases occur in India, Nepal, Bangladesh, Sudan, and 
Brazil
— In South Asia, VL has been reported in 109 districts (India:  n=52; 
Bangladesh:  n=45; Nepal:  n=12)
• High morbidity and mortality
— 500,000 cases and 50,000 deaths per year
— 2.1 million DALYs per year
— Second to Malaria Among Parasitic Diseases
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Public-Private Partnerships For 
Leishmania Vaccine Development
• Public Need (Low/No Market Potential)
—Human VL (India, Bangladesh, Nepal, Ethiopia, Sudan, 
Brazil)
• Private Market (Significant Market Potential)
—Canine VL (Europe, Brazil)
—Human CL (Middle East, Brazil)
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Leishmaniasis Vaccine: A  
Collaborative Effort
Critical Considerations:
• Pathobiology of VL
• Rationale for why a vaccine should work and what we expect 
it to do 
• Animal models:  strengths and weaknesses
• Antigen selection, adjuvant selection, and mechanism of 
protection induced by the vaccine
• Adjuvant Selection
• Affordability/Practicality
• Regulatory issues and path forward
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Immune response during VL
“Human VL is associated with mixed Th1 and Th2 
responses… absence of lymphocyte proliferation and 
production of IFN-γ in vitro associated with progression of L. 
infantum infection to VL in recently infected children. “
“Cure following treatment is accompanied by increased 
IFN- γ and IL-12, decreased IL-10 and TGF-β. The number of 
CD4+CD25+ T cells is increased during active VL and 
decreased at cure… [and] may contribute to the state of 
immunosuppression characteristic of VL.”
WHO Technical Report Series (2010) 949: Control of the leishmaniases
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Mechanisms of vaccine action
• Why should the vaccine work?
—Induces relevant immune responses in animal models 
—Effective adjuvant formulation induces Th1-biased, long-
term memory responses
—Effectively reduces parasite loads in animal models with 
vaccination followed by challenge 
• What do we expect it to do?
—Reduce parasite burden in human and canine reservoirs
—Prevent morbidity and mortality 
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Animal Models For Leishmaniasis
• Mouse
—Disease model for CL
—Infection model for VL
• Hamster
—VL Disease Model
Dog•
—VL Disease Model
• NHP
—Used for both CL and VL, relevance questionable
Feasibility of Vaccine Platforms
Regulatory hurdles*
Live, attenuated, or killed
parasites
high
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Risk
Vaccine Complexity
Vectored 
DNA
Recombinant protein
& adjuvant
highlow
*Similar principles apply to Manufacturing, Storage, Stability.
IDRI’s Leishmaniasis Vaccine 
Candidates
Antigens:
• LEISH-F2 (Human ML, Canine VL)
— Fusion of 3 L. major proteins: TSA, LmSTI1, TSA
• LEISH-F3 (Human VL); designed for visceral leishmaniasis (VL)
— Fusion of 2 conserved Leishmania proteins: NH, SMT
• KSAC (Canine VL)
— Fusion of 4 L. infantum proteins: KMP-11, SMT, A2, CpB
Adjuvants:
• MPL-SE
• GLA-SE
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Vaccine Product Description
• Goal: Prevent human VL
• Antigen:  LEISH-F3 protein
NH SMTN C
The fusion of  nucleoside hydrolase (NH36) from 
L. donovani and sterol 24-c-methyltransferase (SMT) of 
L. infantum results in a 74kD molecule
• Adjuvant:  GLA-SE
• Project Stage: Phase 1 clinical trial started Q1 2012 with LEISH-F3
• Benefits of  LEISH-F3 (formulated NS) over previous antigens
— Same vaccine for VL and CL (protection shown in VL and CL animal models)
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SMT:  % A.A. Identity
L. donovani = 99.7%
L. major = 97%
L. brasiliensis = 86%
NH:  % A.A. Identity
L. infantum = 99.7% 
L. major = 96%
L. brasiliensis = 84%
LEISH-F3 – Potential for VL and CL 
Vaccines
L. amazonensis = 94%L. tropica = 98%
No Homology To Mammalian  Proteins For Either Protein
Adjuvant Selection
A safe, effective, and inexpensive Th1 
adjuvant is crucial for a leishmaniasis
vaccine
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Preclinical VL Vaccine Studies
• Protection in mouse VL models with individual antigens and LEISH-F3 
formulated in GLA-SE or MPL-SE
— Mouse protection predicts efficacy in disease models of VL (dogs, 
hamsters).
• Many adjuvants ineffective, including MF59, SE, Saponin, Alum, and 
others
• Induction of multi-functional T cells in mice
• Induction of multi-functional T cells in NHP
• Protection in mouse model using LEISH-F3 equal to or better than that 
achieved with other vaccine candidates, including recombinant 
proteins/adjuvant, vectored antigen, whole parasite, and crude lysates
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Rational Design of TLR Ligand 
PO4 interfaces 
with TLR-4 
chain 1
Acyl interface 
with TLR-4 
chain 2
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Lipid 
“sandwich” in 
MD2
synthetic TLR-4 agonist
TLR Agonist turns into an 
Adjuvant
Micelle
• Nanomicellar GLA
Emulsified
• GLA-SE
Small 
Particle
• GLA/Alum
Liposome
• GLA-Liposome
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Targeted Nanostructures
20
Organic/inorganic Hybrid Hollow Spheres Prepared from TiO2-stabilised Pickering Emulsion Polymerization
Tao Chen, Patrick J. Colver and Stefan A. F. Bon* Adv. Mater, 2007, 19(17), 2286-2289. View the paper
TLR4 Ligands:  Demonstrate Ideal 
Adjuvant Properties
• Mature TLR4 expression restricted to macrophages and 
dendritic cells in humans (no direct effect on human 
lymphocytes)
• Transient local effects (low levels of IL-10, TGF-β; reduced 
inflammation leads to better central memory)
• Only TLR in approved vaccines (regulatory advantages 
because of familiar and approved mechanism of action)
• SYNTHETIC TLR4 ligand available in millions of doses, and 
COST EFFECTIVE
GLA and MPL formulations stimulate Th1 
immune responses in mice immunized with 
recombinant protein
IFN-γ
0
200
400
600
800
Saline GLA-SE L110f L110f - SE L110f +
GLA-SE (5
ug)
L110f +
MPL-SE
(20 ug)
I
F
N
-
γ
γ γ
γ
 
(
p
g
/
m
l
) L110f Media
IL-5
400
600
800
I
L
-
5
 
(
p
g
/
m
l
)
0 1 2 3 4 5 6 7 8 9
0
1
2
3
4
5
6
7
Saline
GLA-SE
Leish-110f
Leish-110f+SE
Leish-110f+GLA-SE 5ug
Leish-110f+MPL-SE 20ug
Weeks post-infection
L
e
s
i
o
n
 
s
i
z
e
 
(
m
m
)
**
Sa
lin
e
GL
A-
SE
 
20
ug
L1
10
f
L1
10
f+S
E
L1
10
f+G
LA
-
SE
 
5u
g
L1
10
f+M
PL
-
SE
 
20
ug
101
102
103
104
105
106
107
108
p<0.01
P
a
r
a
s
i
t
e
 
b
u
r
d
e
n
 
(
e
a
r
s
)
0
200
Saline GLA-SE L110f L110f - SE L110f +
GLA-SE (5
ug)
L110f +
MPL-SE
(20 ug)
I
L
-
5
 
(
p
g
/
m
l
)
Mean IFN-γ:IL-5 Ratio
0
100
200
Saline GLA-SE L110f L110f - SE L110f +
GLA-SE (5
ug)
L110f +
MPL-SE
(20 ug)
GLA-SE enhances frequency of 
multi-functional, LEISH-F3-specific T 
cells
neg control F3/ GLA-SE F3/ SE
SMT or NH plus adjuvant reduced 
liver parasite burden
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C57BL/6 mice were immunized three times at 21 d intervals with 10µg of the 
indicated antigen in 20µg MPL-SE.
66%
81%
Protection using SMT or LEISH-F3 
in VL model
10-90 
percentile
independent expts
Proof-of-concept using a canine 
vaccine (KSAC/GLA-SE) 
KSAC
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Shared with F3
KSAC+GLA-SE and L110f+GLA-SE protect 
mice from infection by L. major-infected 
sand flies
L. major V1 strain
saline
L110f+GLA-SE
KSAC+GLA-SE
Pre-challenge subclass-
specific IgG responses
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L. major V1 strain
Immunotherapy for Leishmaniasis
Genaro, et al. Clinics in Dermatology, 1996
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LCVTC 101
PID # 101.1008
Day 0 
PID # 101.1008
Day 84
LEISH-F1 + MPL-SE Vaccine 
Brazil CL Trial - Results
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Peru ML Trial  
10 μg Vaccine
Day 0 Day 28
1494
75
21
18
Day 0
Illustration of trends observed in Peru study:  
FACS of one subject’s cells who did not cure 
(chemotherapy only)
Day 84
CD3
1149
64 11
12
Re-stimulated in vitro with LEISH-F1 antigen
Illustration of trends observed in Peru study:  
FACS of one subject’s cells after combination therapy 
(immuno-chemotherapy)
Day 0
102 31 29 18
Re-stimulated in vitro with LEISH-F1 antigen
CD3
Day 84
4154 284 99 67
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Survival curve for the 
open randomized dog trial
p =
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Most severe infections more likely to be assigned to the 
combination immuno-chemo-therapy group.
Summary
F2 vaccine:
• Safe and well tolerated
• Immunogenic 
• Established POC for therapeutic 
vaccine safety, significant efficacies
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